Market research
WOCKPHARMA.NSE Wockhardt Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 309B
- P/E ratio
- 75.77
- Analyst target
- 450
- Dividend yield
- Not available
- Beta
- 0.99
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE049B01025
- Market cap
- 309B
- P/E ratio
- 75.77
- Analyst target
- 450
- Dividend yield
- Not available
- Beta
- 0.99
About
About Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine, as well as offers insulin aspart regular and biphasic drug products. Further, the company offers delivery devices for insulin, including DispoPen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the WOCKPHARMA.NSE discussion.
5 years, 5 months ago
Wockhardt Limited is currently in a long term uptrend where the price is trading 14.6% above its 200 day moving average.
From a valuation standpoint, the stock is 62.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.8.
Wockhardt Limited's total revenue rose by 4.6% to $7B since the same quarter in the previous year.
Its net income has increased by 104.3% to $36M since the same quarter in the previous year.
Finally, its free cash flow fell by 223.5% to $-4B since the same quarter in the previous year.
Based on the above factors, Wockhardt Limited gets an overall score of 4/5.